1. Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma.
- Author
-
Fulciniti M, Martinez-Lopez J, Senapedis W, Oliva S, Lakshmi Bandi R, Amodio N, Xu Y, Szalat R, Gulla A, Samur MK, Roccaro A, Linares M, Cea M, Baloglu E, Argueta C, Landesman Y, Shacham S, Liu S, Schenone M, Wu SL, Karger B, Prabhala R, Anderson KC, and Munshi NC
- Subjects
- Allosteric Regulation, Animals, Apoptosis drug effects, Bone Marrow Cells drug effects, Bone Marrow Cells enzymology, Bone Marrow Cells pathology, Caspases genetics, Caspases metabolism, Cell Line, Tumor, Cell Proliferation drug effects, Cell Survival drug effects, Chromosomes, Human, Pair 14, Chromosomes, Human, Pair 4, Humans, Leukocytes, Mononuclear drug effects, Leukocytes, Mononuclear enzymology, Leukocytes, Mononuclear pathology, Mice, Mice, Nude, Molecular Targeted Therapy, Multiple Myeloma enzymology, Multiple Myeloma pathology, Primary Cell Culture, Protein Binding, RNA, Small Interfering genetics, RNA, Small Interfering metabolism, Receptor, Fibroblast Growth Factor, Type 3 metabolism, Signal Transduction, Translocation, Genetic, Xenograft Model Antitumor Assays, p21-Activated Kinases antagonists & inhibitors, p21-Activated Kinases metabolism, Gene Expression Regulation, Neoplastic, Multiple Myeloma drug therapy, Multiple Myeloma genetics, Protein Kinase Inhibitors pharmacology, Receptor, Fibroblast Growth Factor, Type 3 genetics, p21-Activated Kinases genetics
- Abstract
Dysregulated oncogenic serine/threonine kinases play a pathological role in diverse forms of malignancies, including multiple myeloma (MM), and thus represent potential therapeutic targets. Here, we evaluated the biological and functional role of p21-activated kinase 4 (PAK4) and its potential as a new target in MM for clinical applications. PAK4 promoted MM cell growth and survival via activation of MM survival signaling pathways, including the MEK-extracellular signal-regulated kinase pathway. Furthermore, treatment with orally bioavailable PAK4 allosteric modulator (KPT-9274) significantly impacted MM cell growth and survival in a large panel of MM cell lines and primary MM cells alone and in the presence of bone marrow microenvironment. Intriguingly, we have identified FGFR3 as a novel binding partner of PAK4 and observed significant activity of KPT-9274 against t(4;14)-positive MM cells. This set of data supports PAK4 as an oncogene in myeloma and provide the rationale for the clinical evaluation of PAK4 modulator in myeloma.
- Published
- 2017
- Full Text
- View/download PDF